Study S001979

A Study Investigating the Effect of Cagrilintide on Energy Intake and Appetite in People With Overweight or Obesity

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07557953
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: QUADRUPLE
Status: RECRUITING
Enrollment: 120
Start: 2026-04-30
Primary completion: 2027-04-13
Lead sponsor: Novo Nordisk A/S
Conditions: Overweight; Obesity
Interventions: DRUG:Cagrilintide; DRUG:Placebo Cagrilintide
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1325-8810; OTHER:2025-524206-15; NIH:2025

Registered primary outcomes

Relative change in total energy intake across ad libitum breakfast, lunch, evening meal and snack box [From baseline (Day 2) to end of treatment (Day 127)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.